International Psoriasis Council

Advancing Knowledge. Enhancing Care.

Advancing Knowledge. Enhancing Care.

Amgen Announces New Otezla (Apremilast) Data

news_amgen4-4-22
New data presented by Amgen at the 2022 AAD Congress reinforced the efficacy of apremilast in patients with mild to moderate plaque psoriasis and in patients with palmoplantar pustulosis. This announcement follows the recent US Food and Drug Administration (FDA) expanded Otezla label approval which enabled the use of Otezla across all levels of disease severity. Otezla is the first and only oral therapy FDA approved in adult patients with mild, moderate, and severe plaque psoriasis.
Amgen’s Manufacturing is Worldwide Pioneer in Biotechnology

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Categories

Recent Posts

Getting to Know IPC’s Board Member Claudia de la Cruz: What Inspired Me to Specialize in Psoriasis

Introducing Our Latest IPC Councilors: Experts in Psoriasis Treatment and Research

Shining a Spotlight: Catching up with 2018 IPC Fellow, Jia Qi Chen, PhD

Also Read

disease relapse

Focus on Psoriasis: A Report from the 32nd European Academy of Dermatology and Venereology 2023 Congress (EADV)

Access the latest insights from the 32nd European Academy of Dermatology and Venereology 2023 Congress (EADV) in Berlin, Germany. This report covers significant updates on psoriasis, including the International Psoriasis Council’s Symposium and late-breaking sessions. Download the full EADV Congress Report for a comprehensive overview of psoriasis presentation and treatment advancements.

Read More
Blog - Commentary - Alexander Egeberg - graphic
long-term treatment

Commentary: Looking Beyond Plaque Psoriasis: Novel IL-36 Inhibitor for Prevention of Generalized Pustular Psoriasis Flares

Discover the latest in generalized pustular psoriasis (GPP) treatment with the approval of intravenous spesolimab by regulatory authorities. Read about a 48-week study on the subcutaneous delivery of spesolimab, showcasing promising results for preventing GPP flares. Learn about the evolving landscape of GPP treatment.

Read More

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.